id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-296187-nnv2e7gr	Mulgaonkar, Nirmitee	Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19	2020-08-18		.txt	text/plain	4943	306	57	The SARS-CoV-2 spike glycoprotein, due to its primary interaction with the human angiotensin-converting enzyme 2 (ACE2) cell-surface receptor, is considered as a potential target for drug development. Based on in silico screening followed by in vitro studies, here we report that the existing FDA-approved Bcr-Abl tyrosine kinase inhibitor, imatinib, inhibits SARS-CoV-2 with an IC50 of 130 nM. We provide evidence that although imatinib binds to the receptor-binding domain (RBD) of SARS-CoV-2 spike protein with an affinity at micromolar, i.e., 2.32 ± 0.9 μM levels, imatinib does not directly inhibit the spike RBD:ACE2 interaction – suggesting a Bcr-Abl kinase-mediated fusion inhibition mechanism is responsible for the inhibitory action. This study utilizes in silico methodology followed by in vitro experimental validation to screen existing FDA-approved small molecule drugs specific to the RBD of the spike protein of SARS-CoV-2 to identify repurposable drugs targeting further clinical validation.	./cache/cord-296187-nnv2e7gr.txt	./txt/cord-296187-nnv2e7gr.txt